Maria N Yurova
Overview
Explore the profile of Maria N Yurova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
820
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brzhozovskiy A, Semenov S, Zherebker A, Bugrova A, Yurova M, Zhernov Y, et al.
Int J Mol Sci
. 2025 Feb;
26(4).
PMID: 40004070
The aim of this study was to examine the hepatoprotective activity of multicomponent mixtures of natural origin in the BALB/C mouse model, with subacute liver failure (SALF) induced by the...
2.
Semenov A, Tyndyk M, Von J, Ermakova E, Dorofeeva A, Tumanyan I, et al.
Plants (Basel)
. 2023 Feb;
12(3).
PMID: 36771648
Prostate cancer (PCa) is one of the most common male malignancies worldwide. In the current study, we evaluated the effects of a natural deep eutectic solvent (NADES) extract of roots...
3.
Fedoros E, Tyndyk M, Popovich I, Anikin I, Yurova M, Gubareva E, et al.
J Trace Elem Med Biol
. 2022 Jun;
73:127013.
PMID: 35679766
Background: A standard approach to study the anticancer activity of novel drugs is their testing in animals with inoculated tumors, which has some limitations. An alternative is the use of...
4.
Semenov A, Gubareva E, Ermakova E, Dorofeeva A, Tumanyan I, Radetskaya E, et al.
Plants (Basel)
. 2021 Dec;
10(12).
PMID: 34961206
Benign prostatic hyperplasia (BPH) is a common pathology among aging men. Despite the broad pharmacological interventions, the available remedies to treat BPH are yet not devoid of side effects. Herbal...
5.
Stukov A, Osipov M, Semiglazova T, Filatova L, Alexandrov V, Bespalov V, et al.
Drug Res (Stuttg)
. 2019 Sep;
69(12):683-687.
PMID: 31550733
HER2-positive breast tumors are found in 25-30% of patients with breast cancer and are characterized by aggressive course and reduced sensitivity to both chemotherapy and hormone therapy. The aim of...
6.
Anisimov V, Labunets I, Popovich I, Tyndyk M, Yurova M, Golubev A
Aging (Albany NY)
. 2019 Apr;
11(7):2098-2110.
PMID: 30981207
IGF1 signaling is supposedly a key lifespan determinant in metazoans. However, controversial lifespan data were obtained with different means used to modify IGF1 or its receptor (IGF1R) expression in mice....
7.
Panchenko A, Fedoros E, Pigarev S, Maydin M, Gubareva E, Yurova M, et al.
Exp Ther Med
. 2018 Mar;
15(3):3124-3132.
PMID: 29599844
BP-C3 is a formulation, which comprises lignin-derived polyphenolic composition of benzenepolycarboxylic acids (BP-Cx-1) with iron complex, selenium, ascorbic acid and retinol, and possesses geroprotective activity. The present study examined the...
8.
Anisimov V, Popovich I, Zabezhinski M, Yurova M, Tyndyk M, Anikin I, et al.
Aging (Albany NY)
. 2016 Aug;
8(9):1866-1875.
PMID: 27574962
Effects of long-term application of novel polyphenolic composition BP-C3, containing polyphenolic benzenepolycarboxylic acids, vitamins and minerals on some biomarkers of aging, life span and spontaneous tumorigenesis has been studied in...
9.
Panchenko A, Popovich I, Trashkov A, Egormin P, Yurova M, Tyndyk M, et al.
Biogerontology
. 2015 Oct;
17(2):317-24.
PMID: 26423570
FVB/N wild type and transgenic HER-2/neu FVB/N female mice breed at N.N. Petrov Research Institute of Oncology were under observation until natural death without any special treatment. Age-related dynamics of...
10.
Anisimov V, Popovich I, Zabezhinski M, Egormin P, Yurova M, Semenchenko A, et al.
Cell Cycle
. 2014 Dec;
14(1):46-55.
PMID: 25483062
The perinatal (prenatal and early neonatal) period is a critical stage for hypothalamic programming of sexual differentiation as well as for the development of energy and metabolic homeostasis. We hypothesized...